Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
|
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [41] High-grade serous carcinoma of the ovary
    Westfall, Danielle
    Roma, Andres A.
    Silva, Elvio G.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2009, 13 (04) : 285 - 290
  • [42] COMPARATIVE STUDY OF OVARIAN LOW-GRADE AND HIGH-GRADE SEROUS OVARAIN CARCINOMA
    Mansouri, H.
    Zemni, I.
    Jaidane, O.
    Ayedi, M. A.
    Ben Hassouna, J.
    Hechiche, M.
    Chargui, R.
    Ben Rahal, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A116 - A117
  • [43] Ovarian Yolk Sac Tumor With High-Grade Serous Carcinoma in a 62-Year-Old Woman
    McCarthy, Whitney A.
    Masand, Ramya P.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2016, 24 (04) : 360 - 365
  • [44] Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor
    Imamura, Hiroko
    Ohishi, Yoshihiro
    Aman, Murasaki
    Shida, Kaai
    Shinozaki, Tomoko
    Yasutake, Nobuko
    Sonoda, Keno
    Kato, Kiyoko
    Oda, Yoshinao
    HUMAN PATHOLOGY, 2015, 46 (10) : 1455 - 1463
  • [45] The genomic landscape of high-grade serous ovarian cancer in long-term survivors
    Garsed, Dale W.
    Pandey, Ahwan
    Fereday, Sian
    Alsop, Kathryn
    Wouters, Maartje C.
    Saner, Flurina
    Beach, Jessica A.
    Milne, Katy
    Kennedy, Catherine J.
    Hendley, Joy
    Traficante, Nadia
    Pearce, Celeste L.
    Pike, Malcolm C.
    Ramus, Susan J.
    Kobel, Martin
    Nelson, Brad H.
    Goode, Ellen L.
    deFazio, Anna
    Bowtell, David D.
    CANCER RESEARCH, 2019, 79 (13)
  • [46] Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma
    Matsumoto, Toshihide
    Oda, Yusuke
    Hasegawa, Yoshinori
    Hashimura, Miki
    Oguri, Yasuko
    Inoue, Hisako
    Yokoi, Ako
    Tochimoto, Masataka
    Nakagawa, Mayu
    Jiang, Zesong
    Saegusa, Makoto
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (10): : 1837 - 1850
  • [47] Assessment of the differences in oncologic outcomes between patients with high-grade serous ovarian carcinoma and uterine serous carcinoma
    Kilic, Fatih
    Ersak, Burak
    Cakir, Caner
    Yuksel, Dilek
    Kilic, Cigdem
    Korkmaz, Vakkas
    Tokgozoglu, Nedim
    Toptas, Tayfun
    Boran, Nurettin
    Comert, Gunsu Kimyon
    Ureyen, Isin
    Tasci, Tolga
    Tekin, Ozlem Moraloglu
    Ustun, Yaprak
    Turan, Taner
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (01) : 86 - 94
  • [48] TP53 Mutations in Serous Tubal Intraepithelial Carcinoma and Concurrent Ovarian High-Grade Serous Carcinoma
    Kuhn, E.
    Kurman, R. J.
    Soslow, R. A.
    Han, G.
    Wang, T-L
    Shih, I-M
    MODERN PATHOLOGY, 2011, 24 : 253A - 254A
  • [49] TP53 Mutations in Serous Tubal Intraepithelial Carcinoma and Concurrent Ovarian High-Grade Serous Carcinoma
    Kuhn, E.
    Kurman, R. J.
    Saslow, R. A.
    Han, G.
    Wang, T-L
    Shih, I-M
    LABORATORY INVESTIGATION, 2011, 91 : 253A - 254A
  • [50] Hormonal receptor expression and clinical outcome in ovarian high-grade serous carcinoma
    George, S.
    Sowamber, R.
    Dodds, L.
    Jordan, S. E.
    Paudel, I.
    Huang, M.
    Pinto, A.
    Schlumbrecht, M. P.
    Shaw, P.
    Slomovitz, B. M.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 73 - 73